{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T00:59:34Z","timestamp":1793235574712,"version":"4.5.0"},"reference-count":86,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T00:00:00Z","timestamp":1664409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,11,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>This review covers the recent history of a series of very important natural products and their derivatives that are currently in use or under evaluation in the areas of anti-infectives, important cancer treatments that include antibody drug conjugates, followed by a discussion of type 2 diabetes (T2DM) drugs and angiotensin converting enzyme inhibitors. The current structures of the agents are shown, though in the case of some peptides used in T2DM drugs the standard single letter abbreviation for an amino acid is used.<\/jats:p>","DOI":"10.1093\/nsr\/nwac206","type":"journal-article","created":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T09:58:53Z","timestamp":1664445533000},"source":"Crossref","is-referenced-by-count":170,"title":["Natural products and drug discovery"],"prefix":"10.1093","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4959-2428","authenticated-orcid":false,"given":"David J","family":"Newman","sequence":"first","affiliation":[{"name":"NIH Special Volunteer , Wayne, PA 19087 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,9,29]]},"reference":[{"key":"2022121316323455700_bib1","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1021\/acs.jnatprod.9b01285","article-title":"Natural products as sources of new drugs over the nearly four decades from 01\/1981 to 09\/2019","volume":"83","author":"Newman","year":"2020","journal-title":"J Nat Prod"},{"key":"2022121316323455700_bib2","doi-asserted-by":"publisher","first-page":"10210","DOI":"10.1002\/anie.201601967","article-title":"Artemisinin\u2014a gift from traditional chinese medicine to the world (Nobel lecture).","volume":"55","author":"Tu","year":"2016","journal-title":"Angew Chem Int Ed"},{"key":"2022121316323455700_bib3","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.eng.2018.11.011","article-title":"Artemisinin, the magic drug discovered from Traditional Chinese Medicine","volume":"5","author":"Wang","year":"2019","journal-title":"Engineering"},{"key":"2022121316323455700_bib4","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1756-3305-3-5","article-title":"History of the discovery of the malaria parasites and their vectors","volume":"3","author":"Cox","year":"2010","journal-title":"Parasit Vectors"},{"key":"2022121316323455700_bib5","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S1674-6384(17)60084-4","article-title":"Discovery and development of artemisinin and related compounds","volume":"9","author":"Liu","year":"2017","journal-title":"Chinese Herbal Med"},{"key":"2022121316323455700_bib6","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1038\/nature12051","article-title":"High-level semi-synthetic production of the potent antimalarial artemisinin","volume":"496","author":"Paddon","year":"2013","journal-title":"Nature"},{"key":"2022121316323455700_bib7","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/nrmicro3240","article-title":"Semi-synthetic artemisinin: a model for the use of synthetic biology in pharmaceutical development","volume":"12","author":"Paddon","year":"2014","journal-title":"Nat Rev Microbiol"},{"key":"2022121316323455700_bib8","doi-asserted-by":"publisher","first-page":"105048","DOI":"10.1016\/j.phrs.2020.105048","article-title":"Global research on artemisinin and its derivatives: perspectives from patents","volume":"159","author":"Liu","year":"2020","journal-title":"Pharmacol Res"},{"key":"2022121316323455700_bib9","doi-asserted-by":"publisher","first-page":"8293","DOI":"10.1002\/anie.201802015","article-title":"Total synthesis and biological investigation of (+\/\u2212) -artemisinin: the antimalarial activity of artemisinin is not stereospecific","volume":"57","author":"Krieger","year":"2018","journal-title":"Angew Chem Int Ed"},{"key":"2022121316323455700_bib10","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1016\/j.intimp.2006.03.004","article-title":"Dihydroarteannuin ameliorates lupus symptom of BXSB mice by inhibiting production of TNF-alpha and blocking the signaling pathway NF-kappa B translocation","volume":"6","author":"Li","year":"2006","journal-title":"Int Immunopharm"},{"key":"2022121316323455700_bib11","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.semcancer.2017.02.009","article-title":"From ancient herb to modern drug: Artemisiaannua and artemisinin for cancer therapy","volume":"46","author":"Efferth","year":"2017","journal-title":"Sem Cancer Biol"},{"key":"2022121316323455700_bib12","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1002\/anie.200503071","article-title":"Artemisone\u2014a highly active antimalarial drug of the artemisinin class","volume":"45","author":"Haynes","year":"2006","journal-title":"Angew Chem Int Ed"},{"key":"2022121316323455700_bib13","doi-asserted-by":"publisher","first-page":"111791","DOI":"10.1016\/j.ejmech.2019.111791","article-title":"Current scenario of ferrocene-containing hybrids for antimalarial activity","volume":"185","author":"Xiao","year":"2020","journal-title":"Eur J Med Chem"},{"key":"2022121316323455700_bib14","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.bmcl.2017.12.057","article-title":"Synthesis, in vitro antimalarial activities and cytotoxicities of amino-artemisinin-ferrocene derivatives","volume":"28","author":"de Lange","year":"2018","journal-title":"Bioorg Med Chem Lett"},{"key":"2022121316323455700_bib15","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1002\/slct.202004710","article-title":"Hybrid compounds containing a ferrocene scaffold as potential antimalarials","volume":"6","author":"Peter","year":"2021","journal-title":"ChemistrySelect"},{"key":"2022121316323455700_bib16","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1021\/acsinfecdis.8b00113","article-title":"Evaluation of current and emerging antimalarial medicines for inhibition of Toxoplasmagondii growth in vitro","volume":"4","author":"Radke","year":"2018","journal-title":"ACS Infect Dis"},{"key":"2022121316323455700_bib17","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.pharmthera.2013.12.001","article-title":"Artemisinins: pharmacological actions beyond antimalarial","volume":"142","author":"Ho","year":"2014","journal-title":"Pharm Therap"},{"key":"2022121316323455700_bib18","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1016\/j.biotechadv.2018.01.001","article-title":"Beyond malaria: the inhibition of viruses by artemisinin-type compounds","volume":"36","author":"Efferth","year":"2018","journal-title":"Biotech Adv"},{"key":"2022121316323455700_bib19","doi-asserted-by":"publisher","first-page":"8103","DOI":"10.1002\/chem.201800729","article-title":"Synthesis of artemisinin-derived dimers, trimers and dendrimers: investigation of their antimalarial and antiviral activities including putative mechanisms of action","volume":"24","author":"Frohlich","year":"2018","journal-title":"Chem Eur J"},{"key":"2022121316323455700_bib20","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.chempr.2018.01.012","article-title":"Bioactive compound collections: from design to target identification","volume":"4","author":"Laraia L, Robke","year":"2018","journal-title":"Chem"},{"key":"2022121316323455700_bib21","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1021\/acschembio.8b01004","article-title":"Reverse chemical proteomics identifies an unanticipated human target of the antimalarial artesunate","volume":"14","author":"Gotsbacher","year":"2019","journal-title":"ACS Chem Biol"},{"key":"2022121316323455700_bib22","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1002\/path.2993","article-title":"Gene silencing by siRNAs and antisense oligonucleotides in the laboratory and the clinic","volume":"226","author":"Watts","year":"2012","journal-title":"J Pathol"},{"key":"2022121316323455700_bib23","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1002\/cmdc.201700804","article-title":"Novel peroxides as promising anticancer agents with unexpected depressed antimalarial activity","volume":"13","author":"Coghi","year":"2018","journal-title":"ChemMedChem"},{"key":"2022121316323455700_bib24","doi-asserted-by":"publisher","first-page":"4293","DOI":"10.1021\/ja00379a062","article-title":"Structure of the glycopeptide antibiotic vancomycin. Evidence for an asparagine residue in the peptide","volume":"104","author":"Harris","year":"1982","journal-title":"J Am Chem Soc"},{"key":"2022121316323455700_bib25","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/nature10388","article-title":"Antibiotic resistance is ancient","volume":"477","author":"D\u2019Costa","year":"2011","journal-title":"Nat Biotechnol"},{"key":"2022121316323455700_bib26","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.tim.2012.01.002","article-title":"Antibiotic resistance is ancient: implications for drug discovery","volume":"20","author":"Wright","year":"2012","journal-title":"Trends Microbiol"},{"key":"2022121316323455700_bib27","doi-asserted-by":"publisher","first-page":"E5052","DOI":"10.1073\/pnas.1704125114","article-title":"Peripheral modifications of [\u03a8[CH2NH]Tpg4] vancomycin with added synergistic mechanisms of action provide durable and potent antibiotics","volume":"114","author":"Okano","year":"2017","journal-title":"Proc Natl Acad Sci USA"},{"key":"2022121316323455700_bib28","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1021\/acsinfecdis.0c00258","article-title":"Vancomycin C-terminus guanidine modifications and further insights into an added mechanism of action imparted by a peripheral structural modification","volume":"6","author":"Wu","year":"2020","journal-title":"ACS Infect Dis"},{"key":"2022121316323455700_bib29","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1021\/acs.accounts.0c00569","article-title":"Maxamycins: durable antibiotics derived by rational redesign of vancomycin","volume":"53","author":"Wu","year":"2020","journal-title":"Acc Chem Res"},{"key":"2022121316323455700_bib30","doi-asserted-by":"publisher","first-page":"8656","DOI":"10.1038\/s41598-019-45001-9","article-title":"A landmark in drug discovery based on complex natural product synthesis","volume":"9","author":"Kawano","year":"2019","journal-title":"Sci Rep"},{"key":"2022121316323455700_bib31","first-page":"1802","article-title":"Derivati della parazina II. Sulfonamdopir","volume":"90","author":"Camerino","year":"1960","journal-title":"Gazz Chim Ital"},{"key":"2022121316323455700_bib32","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1002\/bit.260110607","article-title":"Adriamycin, 14-hydroxydaunomycin, a new antitumor antibiotic from S. peucetius var. caesius","volume":"11","author":"Arcamone","year":"1969","journal-title":"Biotechnol Bioeng"},{"key":"2022121316323455700_bib33","doi-asserted-by":"publisher","first-page":"4079","DOI":"10.3390\/jcm10184079","article-title":"Inter-individual variation and cardioprotection in anthracycline-induced heart failure","volume":"10","author":"Norton","year":"2021","journal-title":"J Clin Med"},{"key":"2022121316323455700_bib34","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1039\/D1NP00059D","article-title":"Anthracyclines: biosynthesis, engineering and clinical applications","volume":"39","author":"Hulst","year":"2022","journal-title":"Nat Prod Rep"},{"key":"2022121316323455700_bib35","doi-asserted-by":"publisher","first-page":"419","DOI":"10.2165\/00003088-200342050-00002","article-title":"Pharmacokinetics of pegylated liposomal doxorubicin: review of animal and human studies.","volume":"42","author":"Gabizon","year":"2003","journal-title":"Clin Pharmacokinet"},{"key":"2022121316323455700_bib36","doi-asserted-by":"publisher","first-page":"4421","DOI":"10.3390\/cancers13174421","article-title":"Anthracyclines strike back: rediscovering non-pegylated liposomal doxorubicin in current therapeutic scenarios of breast cancer","volume":"13","author":"Schettini","year":"2021","journal-title":"Cancers"},{"key":"2022121316323455700_bib37","doi-asserted-by":"publisher","first-page":"6883","DOI":"10.1021\/ja00256a070","article-title":"The isolation and structure of a remarkable marine animal antineoplastic constituent: dolastatin 10","volume":"109","author":"Pettit","year":"1987","journal-title":"J Am Chem Soc"},{"key":"2022121316323455700_bib38","doi-asserted-by":"publisher","first-page":"5463","DOI":"10.1021\/ja00196a061","article-title":"Antineoplastic agents. Part 189. The absolute configuration and synthesis of natural (\u2212) -dolastatin 10","volume":"111","author":"Pettit","year":"1989","journal-title":"J Am Chem Soc"},{"key":"2022121316323455700_bib39","author":"Pettit"},{"key":"2022121316323455700_bib40","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1021\/np980321c","article-title":"Symplostatin 1: a dolastatin 10 analogue from the marine cyanobacterium Symplocahydnoides","volume":"61","author":"Harrigan","year":"1998","journal-title":"J Nat Prod"},{"key":"2022121316323455700_bib41","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1021\/np010049y","article-title":"Isolation of dolastatin 10 from the marine cyanobacterium Symploca sp. VP642 and total stereochemistry and biological evaluation of its analogue symplostatin 1","volume":"64","author":"Luesch","year":"2001","journal-title":"J Nat Prod"},{"key":"2022121316323455700_bib42","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1021\/np500931q","article-title":"Targeted natural products discovery from marine cyanobacteria using combined phylogenetic and mass spectrometric evaluation","volume":"78","author":"Salvador-Reyes","year":"2015","journal-title":"J Nat Prod"},{"key":"2022121316323455700_bib43","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1111\/jpy.12309","article-title":"Caldora penicillata gen. nov., comb. nov. (cyanobacteria), a pantropical marine species with biomedical relevance","volume":"51","author":"Engene","year":"2015","journal-title":"J Phycol"},{"key":"2022121316323455700_bib44","author":"Doronina","year":"2002"},{"key":"2022121316323455700_bib45","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1038\/nbt832","article-title":"Development of potent monoclonal antibody auristatin conjugates for cancer therapy","volume":"21","author":"Doronina","year":"2003","journal-title":"Nat Biotech"},{"key":"2022121316323455700_bib46","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: the \u2018biological missile\u2019 for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Sig Transduct Target Ther"},{"key":"2022121316323455700_bib47","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/s13046-020-01711-x","article-title":"MET and RON receptor tyrosine kinases in colorectal adenocarcinoma: molecular features as drug targets and antibody-drug conjugates for therapy","volume":"39","author":"Yao","year":"2020","journal-title":"J Exp Clin Cancer Res"},{"key":"2022121316323455700_bib48","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.drudis.2020.11.002","article-title":"Pharmaceutical strategies in the emerging era of antibody-based biotherapeutics for the treatment of cancers overexpressing MET receptor tyrosine kinase","volume":"26","author":"Yao","year":"2020","journal-title":"Drug Discov Today"},{"key":"2022121316323455700_bib49","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/B978-0-12-417205-0.00005-5","article-title":"Natural products as pharmaceuticals and sources for lead structures","volume-title":"The Practice of Medicinal Chemistry","author":"Newman","year":"2015","edition":"4th edn"},{"key":"2022121316323455700_bib50","doi-asserted-by":"publisher","first-page":"e00395","DOI":"10.1016\/j.btre.2019.e00395","article-title":"Hyper-production of taxol from Aspergillusfumigatus, an endophytic fungus isolated from Taxus sp. of the Northern Himalayan region","volume":"24","author":"Kumar","year":"2019","journal-title":"Biotechnol Rep"},{"key":"2022121316323455700_bib51","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1021\/acs.jnatprod.0c01195","article-title":"Biologically significant and recently isolated alkaloids from endophytic fungi","volume":"84","author":"Daly","year":"2021","journal-title":"J Nat Prod"},{"key":"2022121316323455700_bib52","first-page":"665","article-title":"Recherches experimentales sur la toxicite des urines normales","volume":"8","author":"Bouchard","year":"1884","journal-title":"Compt Rend"},{"key":"2022121316323455700_bib53","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1111\/j.1748-1716.1898.tb00272.x","article-title":"Niere und kreislauf","volume":"8","author":"Tigerstedt","year":"1898","journal-title":"Skand Arch Physiol"},{"key":"2022121316323455700_bib54","first-page":"3","article-title":"Experimental renal hypertension: the discovery of the renin-angiotensin system","volume-title":"Biochemical Regulation of Blood Pressure","author":"Skeggs","year":"1981"},{"key":"2022121316323455700_bib55","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1016\/0006-2952(62)90190-9","article-title":"Potentiation of bradykinin by dimercaptopropanol (BAL) and other inhibitors of its destroying enzyme in plasma","volume":"11","author":"Ferreira","year":"1962","journal-title":"Biochem Pharmacol"},{"key":"2022121316323455700_bib56","doi-asserted-by":"publisher","first-page":"2583","DOI":"10.1021\/bi00815a005","article-title":"Isolation of bradykinin-potentiating peptides from Bothropsjararaca venom","volume":"9","author":"Ferreira","year":"1970","journal-title":"Biochemistry"},{"key":"2022121316323455700_bib57","doi-asserted-by":"publisher","first-page":"4033","DOI":"10.1021\/bi00798a004","article-title":"Angiotensin-converting enzyme inhibitors from the venom of Bothropsjararaca. Isolation, elucidation of structure, and synthesis","volume":"10","author":"Ondetti","year":"1971","journal-title":"Biochemistry"},{"key":"2022121316323455700_bib58","doi-asserted-by":"publisher","first-page":"176","DOI":"10.2183\/pjab1945.46.176","article-title":"Amino acid sequence of bradykinin-potentiating peptide isolated from the venom of Agkistrodonhalys blomhoffii","volume":"46","author":"Kato","year":"1970","journal-title":"Proc Jap Acad"},{"key":"2022121316323455700_bib59","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/nsb0303-155","article-title":"An ACE structure","volume":"10","author":"Hooper","year":"2003","journal-title":"Nat Struct Biol"},{"key":"2022121316323455700_bib60","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1038\/288280a0","article-title":"A new class of angiotensin converting enzyme inhibitors","volume":"288","author":"Patchett","year":"1980","journal-title":"Nature"},{"key":"2022121316323455700_bib61","first-page":"1","article-title":"The design and properties of N-carboxyalkyldipeptide inhibitors of angiotensin-converting enzyme","volume":"57","author":"Patchett","year":"1985","journal-title":"Adv Enzymol Relat Areas Mol Biol"},{"key":"2022121316323455700_bib62","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1038\/nrd1227","article-title":"ACE revisited: a new target for structure-based drug design","volume":"2","author":"Acharya","year":"2003","journal-title":"Nat Rev Drug Discov"},{"key":"2022121316323455700_bib63","doi-asserted-by":"publisher","first-page":"e25952","DOI":"10.1371\/journal.pone.0025952","article-title":"An angiotensin I-converting enzyme mutation (Y465D) causes a dramatic increase in blood ACE via accelerated ACE shedding","volume":"6","author":"Danilov","year":"2011","journal-title":"PLoS One"},{"key":"2022121316323455700_bib64","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1253\/circj.CJ-12-1544","article-title":"Multiple functions of angiotensin-converting enzyme 2 and its relevance in cardiovascular diseases","volume":"77","author":"Kuba K, Imai","year":"2013","journal-title":"Circ J"},{"key":"2022121316323455700_bib65","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/srep00717","article-title":"Molecular recognition and regulation of human angiotensin-I converting enzyme (ACE) activity by natural inhibitory peptides","volume":"2","author":"Masuyer","year":"2012","journal-title":"Sci Rep"},{"key":"2022121316323455700_bib66","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1007\/s00109-014-1172-z","article-title":"ACE in the hole","volume":"92","author":"Luft","year":"2014","journal-title":"J Mol Med"},{"key":"2022121316323455700_bib67","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1210\/endrev\/bnaa029","article-title":"Making, cloning, and the expression of human insulin genes in bacteria: the path to Humulin","volume":"42","author":"Riggs","year":"2021","journal-title":"Endocrine Revs"},{"key":"2022121316323455700_bib68"},{"key":"2022121316323455700_bib69","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1002\/pdi.606","article-title":"Metformin: its botanical background","volume":"21","author":"Bailey","year":"2004","journal-title":"Pract Diabetes Inf"},{"key":"2022121316323455700_bib70","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/S0021-9258(18)86579-6","article-title":"Studies in the metabolic changes induced by administration of guanidine bases. Influence of injected guanidine hydrochloride upon blood sugar content.","volume":"33","author":"Watanabe","year":"1918","journal-title":"J Biol Chem"},{"key":"2022121316323455700_bib71","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1039\/CT9222101790","article-title":"The preparation of methylguanidine, and of \u03b2\u03b2-dimethylguanidine by the interaction of dicyandiamide, and methylammonium and dimethylammonium chlorides respectively","volume":"121","author":"Werner","year":"1922","journal-title":"J Chem Soc Trans"},{"key":"2022121316323455700_bib72","first-page":"1295","article-title":"Du nouveau dans les antidiab\u00e9tiques. La NN dimethylamine guanyl guanidine (N.N.D.G.)","volume":"36","author":"Sterne","year":"1957","journal-title":"Maroc Med"},{"key":"2022121316323455700_bib73","first-page":"17","article-title":"Mechanism of action of antidiabetic biguanides","volume":"72","author":"Sterne","year":"1964","journal-title":"Presse Med"},{"key":"2022121316323455700_bib74","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1056\/NEJM199602293340906","article-title":"Drug therapy: metformin","volume":"334","author":"Bailey","year":"1996","journal-title":"N Engl J Med"},{"key":"2022121316323455700_bib75","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1056\/NEJM199508313330902","article-title":"Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus","volume":"333","author":"DeFronzo","year":"1995","journal-title":"N Engl J Med"},{"key":"2022121316323455700_bib76","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1007\/s00125-017-4318-z","article-title":"Metformin: historical overview","volume":"60","author":"Bailey","year":"2017","journal-title":"Diabetilogia"},{"key":"2022121316323455700_bib77","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1021\/np9604893","article-title":"Natural products in drug discovery and development","volume":"60","author":"Cragg","year":"1997","journal-title":"J Nat Prod"},{"key":"2022121316323455700_bib78","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1021\/np030096l","article-title":"Natural products as sources of new drugs over the period 1981\u20132002","volume":"66","author":"Newman","year":"2003","journal-title":"J Nat Prod"},{"key":"2022121316323455700_bib79","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1021\/np068054v","article-title":"Natural products as sources of new drugs over the last 25 years","volume":"70","author":"Newman","year":"2007","journal-title":"J Nat Prod"},{"key":"2022121316323455700_bib80","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1021\/np200906s","article-title":"Natural products as sources of new drugs over the 30 years from 1981 to 2010","volume":"75","author":"Newman","year":"2012","journal-title":"J Nat Prod"},{"key":"2022121316323455700_bib81","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1021\/acs.jnatprod.5b01055","article-title":"Natural products as sources of new drugs 1981 to 2014","volume":"79","author":"Newman","year":"2016","journal-title":"J Nat Prod"},{"key":"2022121316323455700_bib82","doi-asserted-by":"publisher","first-page":"749010","DOI":"10.3389\/fendo.2021.749010","article-title":"Therapeutic targeting of SGLT2: a new era in the treatment of diabetes and diabetic kidney disease","volume":"12","author":"Shaffner","year":"2021","journal-title":"Front Endocrinol"},{"key":"2022121316323455700_bib83","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.2337\/dbi18-0006","article-title":"Sodium-glucose cotransporter 2 inhibitors: a case study in translational research","volume":"68","author":"Beitelshees","year":"2019","journal-title":"Diabetes"},{"key":"2022121316323455700_bib84","doi-asserted-by":"publisher","first-page":"17842","DOI":"10.1021\/acsomega.8b02507","article-title":"Biguanide antidiabetic drugs: imeglimin exhibits higher proton basicity but smaller lithium-cation basicity than metformin in vacuo","volume":"3","author":"Raczyn\u0144ska","year":"2018","journal-title":"ACS Omega"},{"key":"2022121316323455700_bib85","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1021\/acs.oprd.1c00108","article-title":"Kilogram-scale GMP manufacture of tirzepatide using a hybrid SPPS\/LPPS approach with continuous manufacturing","volume":"25","author":"Frederick","year":"2021","journal-title":"Org Process Res Dev"},{"key":"2022121316323455700_bib86","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.2147\/DDDT.S358989","article-title":"Designing a dual GLP-1R\/GIPR agonist from tirzepatide: comparing residues between tirzepatide, GLP-1, and GIP","volume":"16","author":"Wang","year":"2022","journal-title":"Drug Design Develop Ther"}],"container-title":["National Science Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/nsr\/advance-article-pdf\/doi\/10.1093\/nsr\/nwac206\/46198006\/nwac206.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/nsr\/article-pdf\/9\/11\/nwac206\/47839762\/nwac206.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/nsr\/article-pdf\/9\/11\/nwac206\/47839762\/nwac206.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T13:25:54Z","timestamp":1670937954000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/nsr\/article\/doi\/10.1093\/nsr\/nwac206\/6730726"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,29]]},"references-count":86,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11,9]]}},"URL":"https:\/\/doi.org\/10.1093\/nsr\/nwac206","relation":{},"ISSN":["2095-5138","2053-714X"],"issn-type":[{"value":"2095-5138","type":"print"},{"value":"2053-714X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,11]]},"published":{"date-parts":[[2022,9,29]]},"article-number":"nwac206"}}